Coverage
-
September 14, 2015
Takeda Pharmaceutical Company Ltd. said Friday that more than 96 percent of claimants have sought a share of the Japanese drugmaker's proposed deal of up to $2.4 billion to resolve claims that it hid the alleged bladder cancer risks of its diabetes drug Actos.
15 other articles on this case.
View all »